CA Patent

CA2681718A1 — Hiv-1 protease inhibitors

Assigned to Massachusetts Institute of Technology · Expires 2008-10-02 · 18y expired

What this patent protects

Described are novel protease inhibitors and methods for using said protease inhibitors in the treatment of human immunodeficiency virus (HIV) infection.

USPTO Abstract

Described are novel protease inhibitors and methods for using said protease inhibitors in the treatment of human immunodeficiency virus (HIV) infection.

Drugs covered by this patent

lenacapavir-sodium (LENACAPAVIR SODIUM)

Patent Metadata

Patent number: CA2681718A1
Jurisdiction: CA
Classification: —
Expires: 2008-10-02
Drug substance claim: No
Drug product claim: No
Assignee: Massachusetts Institute of Technology
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.